{
    "nct_id": "NCT03819465",
    "official_title": "A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)",
    "inclusion_criteria": "* Histologically or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation\n* No prior chemotherapy or any other systemic therapy for metastatic NSCLC\n* Prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, if progression has occurred >12 months from end of last therapy\n* Known tumor PD-L1 status\n* Tumors that lack activating EGFR mutations and ALK fusions or documented local test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care\n* WHO/ECOG status at 0 or 1 at enrollment\n* Life expectancy of at least 12 weeks\n* Troponin I or T â‰¤ ULN (per institutional guidelines)\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 130 Years",
    "exclusion_criteria": "* Active or prior documented autoimmune or inflammatory disorders\n* History of active primary immunodeficiency\n* Any prior chemotherapy or any other systemic therapy for metastatic NSCLC\n* Untreated CNS metastases",
    "miscellaneous_criteria": ""
}